---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219424"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2026-05-12T20:10:18+00:00"
generated_at: "2026-05-12T21:07:38.707912+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PepGen Q1 net loss $17.8M; cash $132.3M; 10 mg/kg DM1 cohort fully enrolled

## Summary
- Net loss of $17.8M ($0.26 per share) vs $30.2M loss in Q1 2025; R&D spend down to $13.0M from $25.4M.
- Cash, equivalents and marketable securities $132.3M; funding seen into 2H 2027.
- FREEDOM2-DM1 5 mg/kg cohort showed favorable safety, splicing and vHOT trends; 10 mg/kg cohort fully enrolled with data expected 2H 2026.
- FDA partial clinical hold on FREEDOM2 relates to preclinical studies; timing of ongoing trial not impacted.
- 13 patients enrolled in open-label extension at 5 mg/kg with no discontinuations.

## SEC filing metadata
- accession: 0001193125-26-219424
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2026-05-12T20:10:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/0001193125-26-219424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/pepg-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219424
- JSON: https://secwatch.observer/filing/0001193125-26-219424.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.